Abstract
It has been a conventional notion that cytoplasmic recombinant expression leads to either soluble protein or inclusion bodies. In the latter case, it was always assumed that proteins in inclusion bodies (IBs) are more or less unfolded and hence require complete denaturing condition for solubilization, which uses strong detergents, urea or guanidine hydrochloride. However, we often observe distribution of expressed proteins in both soluble and insoluble fractions. In such expression, IBs are often loose and of flocculate morphology. We believe that such distribution is due to association of near native structures of the expressed proteins, which cause either aggregation into insoluble fractions or unstable soluble proteins. In our experience, although not reported by others, interleukin-1α, interferon-γ, tumor necrosis factors, fibroblast growth factors, His-tagged fyn kinase and many other proteins showed such behavior. If this occurs, we have experienced problems of instability, low yield and insolubility whether purification is done from the soluble fraction or by refolding of IBs. Arginine has shown great promise in non-denaturaing solubilization of some of these proteins we have tested.
Keywords: Non-denaturing solubilization, inclusion bodies, arginine, GFP, FGF-20
Current Pharmaceutical Biotechnology
Title: Non-Denaturing Solubilization of Inclusion Bodies
Volume: 11 Issue: 3
Author(s): Kouhei Tsumoto, Ryota Abe, Daisuke Ejima and Tsutomu Arakawa
Affiliation:
Keywords: Non-denaturing solubilization, inclusion bodies, arginine, GFP, FGF-20
Abstract: It has been a conventional notion that cytoplasmic recombinant expression leads to either soluble protein or inclusion bodies. In the latter case, it was always assumed that proteins in inclusion bodies (IBs) are more or less unfolded and hence require complete denaturing condition for solubilization, which uses strong detergents, urea or guanidine hydrochloride. However, we often observe distribution of expressed proteins in both soluble and insoluble fractions. In such expression, IBs are often loose and of flocculate morphology. We believe that such distribution is due to association of near native structures of the expressed proteins, which cause either aggregation into insoluble fractions or unstable soluble proteins. In our experience, although not reported by others, interleukin-1α, interferon-γ, tumor necrosis factors, fibroblast growth factors, His-tagged fyn kinase and many other proteins showed such behavior. If this occurs, we have experienced problems of instability, low yield and insolubility whether purification is done from the soluble fraction or by refolding of IBs. Arginine has shown great promise in non-denaturaing solubilization of some of these proteins we have tested.
Export Options
About this article
Cite this article as:
Tsumoto Kouhei, Abe Ryota, Ejima Daisuke and Arakawa Tsutomu, Non-Denaturing Solubilization of Inclusion Bodies, Current Pharmaceutical Biotechnology 2010; 11 (3) . https://dx.doi.org/10.2174/138920110791111924
DOI https://dx.doi.org/10.2174/138920110791111924 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Agents for Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics The Role of P-Glycoprotein in the Pharmacokinetics and Tissue Distribution of a Hepatitis C Virus Protease Inhibitor
Drug Metabolism Letters The Biological Functions of NF-κB1 (p ) and its Potential as an Anti-Cancer Target
Current Cancer Drug Targets Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design The Therapeutic Potential of 4-1BB (CD137) in Cancer
Current Cancer Drug Targets Differential Conservation of Nucleotides and Conservation/Mutation Correlations Between Nucleotides, with Special Reference to CXC 1 and 4 and FP Receptors Involved in Immune Regulation
Endocrine, Metabolic & Immune Disorders - Drug Targets Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design Mechanisms of Thrombosis, Available Treatments and Management Challenges Presented by Thromboangiitis Obliterans
Current Medicinal Chemistry Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Biomolecular Pathogenesis of Borderline Ovarian Tumors: Focusing Target Discovery Through Proteogenomics
Current Cancer Drug Targets Plant Phenylpropanoids as Emerging Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research The Role of Estradiol and Progesterone in Mucosal HIV-1 Infection, Transmission and Pathogenesis
Current Women`s Health Reviews A novel machine learning method for cytokine-receptor interaction prediction
Combinatorial Chemistry & High Throughput Screening Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Telomeres and their Role in Aging and Longevity
Current Vascular Pharmacology Review on Novel Carrier System: Liposomes and Proliposomes
Drug Delivery Letters